Trial Profile
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 01 Feb 2023 Results assessing the efficacy and safety of atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma, published in the Journal of Cancer Research and Clinical Oncology.
- 27 May 2020 Status changed from active, no longer recruiting to completed.
- 08 May 2020 This trial has been completed in Germany according to European Clinical Trials Database record.